Long-term follow-up of patients undergoing renal sympathetic denervation

• DOI: 10.1007/s00392-022-02056-5
• Publication Date: 2022-07-18T17:02:36Z
• Authors: Victor J. M. Zeijen; Lida Feyz; Rajiv Nannan Panday; Kevin Veen; Jorie Versmissen; Isabella Kardys; Nicolas M. Van Mi...; Joost Daemen
• Keywords: Regimen; Antihypertensive drug; Renal sympathetic denervation

Renal denervation (RDN) proved to significantly lower blood pressure (BP) at 2-6 months in patients on and off antihypertensive drugs. Given a lack of longer-term follow-up data, our aim was assess the safety efficacy RDN up five years taking into account drug regimen changes over time.In present single-center study, underwent for (therapy resistant) hypertension. Patients protocolized yearly out years. Data were collected 24-h ambulatory BP office monitoring, renal function, regimen, events, including non-invasive artery imaging 6/12 months. Efficacy analyses performed using linear mixed-effects models.Seventy-two with mean age 63.3 ± 9.5 (SD) (51% female) included. Median time 3.5 Clark's Completeness Index 72%. Baseline daytime 146.1/83.7 17.4/12.2 mmHg under number 4.9 2.7 defined daily doses (DDD). At years, systolic as calculated from mixed model 120.8 (95% CI 114.2-127.5) diastolic 73.3 69.4-77.3) mmHg, implying reduction -20.9/-8.3 compared baseline estimates (p < 0.0001). The DDDs remained stable = 0.87). No procedure-related major adverse events resulting long-term consequences observed.The BP-lowering effect safely maintained least post-procedure reflected by significant decrease absence escalating therapy time.